title: Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
abstract: The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied.
  
  
  METHODS
  Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p.
  
  
  RESULTS
  The survival rate of group IV was better than that of the other groups (p < 0.05). The area under the ascitic platinum concentration-time curve and tissue concentrations of platinum in the omentum after 24 hours of treatment were higher in group IV than in groups II or III (p < 0.05). The platinum concentrations in the kidneys of group IV were lower than in group III (p < 0.05).
  
  
  CONCLUSIONS
  The HAP-CBDCA combination enhances the anti-tumor effects of the drug and reduces the nephrotoxicity in rats with peritoneal carcinomatosis.
authors.affiliation: Department of Gastroenterological Surgery, Nagoya City University, Graduate School of Medical Sciences, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. takeyama@med.nagoya-cu.ac.jp
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Takeyama
authors.forename: Noriaki
authors.initials: N
authors.lastname: Mohri
authors.forename: Isamu
authors.initials: I
authors.lastname: Mizuno
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Akamo
authors.forename: Hirozumi
authors.initials: H
authors.lastname: Sawai
authors.forename: Tadao
authors.initials: T
authors.lastname: Manabe
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Yotsuyanagi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D051381:Rats
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin